PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

With 15+ years of expertise in proteins expression in R&D and production, ExpreS2ion Biotechnologies have developed a proprietary Drosophila S2 systems (ExpreS2) optimized for secreted or secretable protein expression that we offer on fee for service basis.

If you meet problems in your protein production, such as:
* low yield or no yield
* issues with protein cleavage/degradation
* lack of batch reproducibility due to variable glycosylation
 
ExpreS2ion Biotechnologies can provide its expertise and ExpreS2 platform to help you to solve your problems:
* Transient & stable expression
* Medium throughput screening service
* Establishment of stable expression pools
* Production re-batching
* Selection of high-producing mini-pools and monoclonal cell lines
* Protein Purification
* Analytics
* Transfer to cGMP facilities
 
Assets of the ExpreS2:
* Rapid process to produce & purified protein from Bioreactors (6 weeks)
* high yield: 10x-100x the yield compared to proteins produced in baculo virus or HEK293 cells
* Homogeneous product (no cell lysis)
* Correctly folded proteins
* Growth at 25 °C, no need of CO2 incubator
* Heterodimer production
* VLP production
* High reproducibility between batches
* High expertise for transfer from lab to cGMP facilities
* Compatible to perfusion, batch and fed-batch processes
* Reduce risk of human viral contaminants
* Significant savings in manufacturing & infrastructure
* Rapid scale up for pandemic response
 
Applications:
* Crystallography studies, ELISA tests
* Development of therapeutic & prophylactic vaccines
* Diagnostic kits, companion diagnostic kits
* Therapeutic proteins
 
Highlights from ExpreS2ion Biotechnologies:
* More than 250 proteins produced including: viral & parasite antigens, VLPs, plasma proteins
* Major Pharma have already adopted this technology for their vaccines development
* Projects validated by regulatory authorities and already in clinical phase II for malaria vaccines
 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026